论文部分内容阅读
死亡是肥厚型心肌病(HCM)常见并发症,多为猝死且难预测。严重室性心律失常亦多见并易伴猝死。过去十年,β—阻滞剂是主要的治疗选择,但只能减轻症状不能降低心律失常发生率。现在倡用的异搏定可减轻症状、改善运动耐量,并可能减轻心肌肥厚,但对HCM的抗心律失常效应所知甚少。乙胺碘呋酮是广谱抗室性和室上性心律失
Death is a common complication of hypertrophic cardiomyopathy (HCM), mostly sudden and unpredictable. Severe ventricular arrhythmias are also more common and easily accompanied by sudden death. Beta-blockers have been the primary treatment option in the past decade, but only reducing symptoms can not reduce the incidence of arrhythmias. Verapamil now being introduced may reduce symptoms, improve exercise tolerance, and may reduce cardiac hypertrophy, but little is known about the anti-arrhythmic effects of HCM. Amiodarone is broad-spectrum anti-ventricular and supraventricular arrhythmias